Start Your Search
Best abstracts selected from submissions 2 (ID 2)
- Event: ACLC 2018
- Type: Oral Session
- Presentations: 1
- Coordinates: 11/08/2018, 16:20 - 17:00, Jade Ballroom
OA04 - Factors Influencing the Non-Administration of Chemotherapies in Patients Who Progressed After (ID 154)
16:20 - 17:00 | Author(s): S. Watanabe
Patients with EGFR-mutation-positive non-small-cell lung cancer (EGFR-NSCLC) who are treated with both cytotoxic chemotherapy and EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have better survival outcomes than those who are only treated with EGFR-TKIs. Limited information is available about the factors that influence the non-administration of cytotoxic chemotherapies after the failure of EGFR-TKIs.
We reviewed the medical records of EGFR-NSCLC patients who received EGFR-TKIs as a first-line treatment at the National Cancer Center Hospital between January 2010 and December 2016. Computed tomography data regarding the number of metastatic organs, at the time of progressive disease (PD), which reflects the tumor burden, was retrieved. EGFR-TKIs use beyond PD was also investigated. We performed a multivariate logistic regression analysis to determine the factors influencing the non-administration of cytotoxic chemotherapies.
A total of 393 patients received EGFR-TKIs as a first-line treatment during the study period. After the exclusion of 96 patients who were receiving ongoing EGFR-TKIs treatment, 297 patients (103 men, 194 women) were included in this analysis. The median age was 68 years (range, 33?87 years), and 291 patients had an adenocarcinoma histology; 155 had deletions in exon 19, 132 had the L858R point mutation in exon 21, and 10 had other minor mutations. An Eastern Cooperative Oncology Group performance status (PS) of 0